Oseltamivir: another case of regulatory failure?

@article{Cohen2014OseltamivirAC,
  title={Oseltamivir: another case of regulatory failure?},
  author={Deborah Cohen},
  journal={BMJ : British Medical Journal},
  year={2014},
  volume={348}
}
  • D. Cohen
  • Published 2014
  • Medicine
  • BMJ : British Medical Journal
Governments around the world stockpiled oseltamivir for a flu pandemic despite uncertainty about its harms. Deborah Cohen investigates what the regulators knew and whether their response was adequate 

Topics from this paper

The Tamiflu fiasco and lessons learnt
TLDR
This article takes a comprehensive relook on the Tamiflu saga, and suggests some ways and means to avoid a similar situation in the future. Expand
Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza
TLDR
Whether there is an association between financial conflicts of interest and the favorable presentation of evidence in systematic reviews on the use of neuraminidase inhibitors for the prophylaxis and treatment of influenza is determined. Expand
Enhanced inhibition of influenza virus infection by peptide-noble metal nanoparticle conjugates
TLDR
It is demonstrated that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of silver ions may enable the design of even more potent anti-microbial inhibitors. Expand
Enhanced inhibition of influenza virus infection by peptide–noble-metal nanoparticle conjugates
TLDR
It is demonstrated that conjugation of FluPep to gold and silver nanoparticles enhances its antiviral potency; the antimicrobial activity of silver ions may enable the design of even more potent antimicrobial inhibitors, capable of targeting both influenza and bacterial co-infections. Expand

References

SHOWING 1-10 OF 24 REFERENCES
Complications: tracking down the data on oseltamivir
  • D. Cohen
  • Medicine
  • BMJ : British Medical Journal
  • 2009
A Cochrane group’s attempt to reproduce an analysis underpinning the use of oseltamivir in pandemic influenza hit a brick wall. Deborah Cohen retraces its steps
Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010
TLDR
Assessment of oseltamivir safety before and during the 2009 influenza A (H1N1) pandemic using biologically plausible risk intervals, particularly focusing on psychiatric events. Expand
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
TLDR
Oseltamivir was effective and well tolerated in the treatment of natural influenza infection in adults and was associated with higher symptom scores, less viral shedding, and improved health, activity, and sleep quality. Expand
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
TLDR
Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza. Expand
USE OF THE SELECTIVE ORAL NEURAMINIDASE INHIBITOR OSELTAMIVIR TO PREVENT INFLUENZA
A BSTRACT Background Safe and effective antiviral agents are needed to prevent infection with influenza A and B viruses. Oseltamivir (GS4104), which can be administered orally, is the prodrug ofExpand
UK scientific adviser criticises UK planning for flu pandemic
  • A. O'dowd
  • Medicine
  • BMJ : British Medical Journal
  • 2009
TLDR
The government’s chief scientific adviser is not convinced that the United Kingdom has the right plans in place to cope with avian flu, but plans to deal with that were appropriate for now. Expand
Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
TLDR
The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications. Expand
Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships
TLDR
Following the review of known clinical cases of this type, and in the light of the study of animal experiments and the latest laboratory findings, it is proposed to classify adverse reactions to Tamiflu as follows: Sudden onset adverse reactions typically occurring after taking one or two doses of Tamifflu; these result from the central nervous system suppressant action of oseltamivir. Expand
Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir
TLDR
This review summarizes the results of a comprehensive assessment of the company’s own preclinical and clinical studies, post-marketing spontaneous adverse event reporting, epidemiological investigations utilizing health claims and medical records databases and an extensive review of the literature on neuropsychiatric abnormalities reported in patients with influenza. Expand
Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey.
TLDR
The results confirmed anecdotal evidence of poor adherence, provided timely information with which to assist decision-making, and formed part of the body of growing evidence that contributed to policy changes to restrict widespread use of prophylaxis for school contacts of confirmed cases of influenza A(H1N1)v. Expand
...
1
2
3
...